| SCHEDULE OF OUTSTANDING WARRANT |
The
following table provides a summary of outstanding warrants to purchase shares of common stock as of March 31, 2026:
SCHEDULE OF OUTSTANDING WARRANT
| Reference | |
Shares
Underlying
Outstanding
Warrants | | |
Exercise
Price | | |
Description | |
Classification |
| (a) | |
| 992,000 | | |
| $2.50
- $3.125 | | |
November
2025 Warrants | |
Equity |
| (b) | |
| 134,314 | | |
| $1.90
- $4.05 | | |
April
2025 Warrants | |
Equity |
| (c) | |
| 22,063 | | |
| $4.3625 | | |
March
2025 Warrants | |
Equity |
| (d) | |
| 1,864,545 | | |
| $7.05
- $8.8125 | | |
August
2024 Warrants | |
Equity |
| (e) | |
| 16,811 | | |
| $24.56 | | |
February
2024 Warrants | |
Equity |
| (f) | |
| 162,881 | | |
| $7.05
- $23.51 | | |
2023
Notes Warrants | |
Equity |
| (g) | |
| 73,474 | | |
| $54.56
- $41,400 | | |
Other
Warrants | |
Equity
& Liability |
| | |
| 3,266,088 | | |
| | | |
| |
|
| (a) |
|
On
November 14, 2025, the Company issued 880,000 equity classified warrants to certain institutional investors with the Series B Preferred
Stock Financing. The warrants have an exercise price of $2.50 per share and are immediately exercisable for shares of common stock
and expire on January 7, 2031. In connection with the Series B Preferred Stock Financing, there were 112,000 warrants issued to placement
agent. The placement agent warrants were immediately exercisable with an exercise price of $3.125 per share and expire on January
7, 2031. |
| (b) |
|
On
April 24, 2025, the Company issued 1,304,878 equity classified warrants (Common Warrants and placement agent warrants) in connection
with the Inducement Letter of the 2025 April warrant inducement. The Common Warrants have an exercise price of $1.90 per share and
are immediately exercisable for shares of common stock. One half of the Common Warrants will expire on October 26, 2026, and the
other half will expire on April 24, 2030. The placement agent warrants were immediately exercisable with an exercise price of $4.05
per share and expire on April 24, 2030. As of March 31, 2026, there have been 1,170,564 warrants exercised at an exercise price of
$1.90 per share. |
| |
|
|
| (c) |
|
On
March 31, 2025, in connection with the 2025 Registered Direct Offering and 2025 March Warrant Offering, the Company issued equity
classified warrants to purchase 652,439 shares to certain institutional investors and the placement agent. The warrants were issued
in connection with the 2025 Registered Direct Offering and 2025 March Warrant Offering. The 630,376 investor warrants have an exercise
price of $3.24 per share. One half of the warrants will expire on October 1, 2026, and the other half will expire on March 31, 2030.
The 22,063 placement agent warrants have an exercise price of $4.3625 per share and expire on March 30, 2030. In connection with
the 2025 April Warrant Inducement, 630,376 investor warrants were exercised. As of March 31, 2026, the placement agent warrants remain
outstanding. |
| |
|
|
| (d) |
|
On
August 29, 2024, in connection with the 2024 Registered Direct Offering and 2024 August Warrant Inducement, the Company
issued equity classified warrants to purchase 1,964,666 shares to certain institutional investors and the placement agent. The warrants
were issued in connection with the 2024 Registered Direct Offering and the 2024 August Warrant Inducement. The 1,914,466 investor
warrants have an exercise price of $7.05 per share. One half of the warrants expire on May 21, 2026, and the other half expire on
November 21, 2029. The 50,200 placement agent warrants have an exercise price of $8.8125 per share and expire on August 28, 2029.
As of March 31, 2026, there have been 100,121 warrants exercised. |
| (e) |
|
On
February 12, 2024, the Company issued 497,047 equity classified warrants (Series A Warrants, Series B Warrants and placement agent
warrants) in connection with the Inducement Letter for the 2024 February warrant inducement and related warrant restructuring. The
Series A and Series B Warrants were immediately exercisable with an exercise price of $15.90 per share and expire on August 14, 2025
and May 12, 2028, respectively. The placement agent warrants were immediately exercisable with an exercise price of $24.56 per share
and expire on May 12, 2028. In connection with the 2024 August Warrant Inducement, 480,236 Series A and Series B warrants were exercised.
As of March 31, 2026, the placement agent warrants remain outstanding. |
| |
|
|
| (f) |
|
On
October 25, 2023, and November 28, 2023, the Company issued warrants to purchase 83,714 shares and 167,428 shares, respectively.
The warrants were immediately exercisable with an exercise price of $23.51 per share and expire on October 25, 2028, and November
28, 2028, respectively. In January 2024, a holder of the warrants exercised 88,261 warrants at an exercise price of $23.51 per share.
In August 2024, an inducement letter was issued to a holder of 133,334 warrants to reduce the exercise price from $23.51 to $7.05
per share. |
| |
|
|
| (g) |
|
At
various dates through September 30, 2023, the Company assumed or issued a total of 73,474 warrants to provide holders the right to
purchase common stock at exercise prices ranging from $54.60 - $41,400 per share. A total of 2,778 of the outstanding warrants are
public warrants which trade on the OTC Pink Open Market under the ticker symbol ENSCW. A total of 2,901 outstanding warrants (issued
in connection with the 2021 and 2022 Notes) are liability-classified due to certain cash settlement features embedded within the
warrant agreements. The remaining warrants are equity classified. The warrants expire beginning June 30, 2026, through August 7,
2028. |
|